Spherix Global Insights today announces the release of its latest Market Dynamix(TM): Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a sizable population of patients eligible for ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease of the blood. Evidence suggests that PNH may increase the chances of developing chronic kidney disease (CKD). PNH is characterized ...
These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance. In ...
In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment. Carlos M. De Castro, MD: I’d love to say we need more studies, studying ...
Dr Haumschild continues leading an expert discussion surrounding key strategies and pain points in PNH treatment. Please describe the significance of the different efficacy end points explored for ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...
Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH studies ...
Apellis Pharmaceuticals is taking a victory lap. Less than two weeks after the FDA approved Apellis’ C3 inhibitor pegcetacoplan, marketed as Empaveli, for patients with a rare blood disorder known as ...
The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease that can cause fatigue due to anemia. PNH is closely associated with fatigue due to a loss of red blood cells, leading to anemia. This ...
Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results